AstraZeneca said on Friday that a new study showed its dry powder inhaler Symbicort (budesonide and formoterol) was superior to either inhaled corticosteroids or long acting beta-agonists given as monotherapy in COPD.
Anders Ekblom, Vice President, Respiratory Therapy Area, AstraZeneca, said in a statement the findings provided “robust support” for the company’s application earlier this year to extend the drug’s asthma label to COPD.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!